Salermide 是一种 Sirt1 和 Sirt2 的抑制剂，可诱导强烈的癌症特异性细胞凋亡。

Salermide is an inhibitor of Sirt1 and Sirt2, causing strong cancer-specific apoptotic cell death.

Salermide prompts tumour-specific cell death in a wide range of human cancer cell lines. The antitumour activity of Salermide is primarily because of a massive induction of apoptosis. Salermide induces apoptosis in cancer but not in normal cells. It induces strong apoptosis without any evident effect on the cell cycle in all the cancer cell lines analysed except in non-tumorigenic MRC5 cells. The induction of apoptosis is cell-type-specific and dose-dependent[1].

Salermide is well tolerated by mice at concentrations up to 100?μM. Its feeding does not produce any adverse health effects in mice as monitored by diet consumption, body-weight gain, and postural and behavioural changes[1].

Cell viability is determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described earlier. IC50 index is calculated using four Salermide concentrations (25, 50, 75 and 100?μm) for 24?h. The percentage of apoptotic cells is determined with the FACSCalibur apparatus.(Only for Reference)

1105698-15-4

C26H22N2O2

394.474

DMSO:39.5 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years